Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
RPRXRoyalty Pharma(RPRX) Zacks Investment Research·2024-02-17 05:31

Royalty Pharma (RPRX) reported 736millioninrevenueforthequarterendedDecember2023,representingayear−over−yeardeclineof30.8736 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 30.8%. EPS of 1.15 for the same period compares to 1.56ayearago.Thereportedrevenuerepresentsasurpriseof+4.711.56 a year ago. The reported revenue represents a surprise of +4.71% over the Zacks Consensus Estimate of 702.9 million. With the consensus EPS estimate being $1.03, the EPS surprise was +11.65%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to det ...